作者: Kathryn L. Schwienteck , Matthew L. Banks
DOI: 10.1016/J.DRUGALCDEP.2015.08.022
关键词:
摘要: Abstract Background Methamphetamine addiction is a significant public health problem for which no Food and Drug Administration-approved pharmacotherapies exist. Preclinical drug vs. food choice procedures have been predictive of clinical medication efficacy in the treatment opioid cocaine addiction. Whether preclinical are candidate effects other abused drugs, such as methamphetamine, remains unclear. The present study aim was to determine continuous 7-day with monoamine releaser d -amphetamine uptake inhibitor methylphenidate on methamphetamine choice. In addition, were also examined. Methods Behavior maintained under concurrent schedule delivery (1-g pellets, fixed-ratio 100 schedule) injections (0–0.32 mg/kg/injection, 10 male rhesus monkeys ( n = 4). dose–effect functions determined daily before during periods intravenous (0.01–0.1 mg/kg/h), (0.032–0.32 mg/kg/h), or (0.1–0.32 mg/kg/h). Results During saline treatment, increasing doses resulted corresponding increase Continuous treatments -amphetamine, did not significantly attenuate up that decreased rates operant responding. However, 0.1 mg/kg/h eliminate two monkeys. Conclusions subchronic results support utility evaluate medications Furthermore, these confirm extend previous demonstrating differential pharmacological mechanisms between